Microbial products in allergy prevention and therapy

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 58, Issue 6, 2003, Pages 461-471

  Matricardi, Paolo M ^a   Bjorksten, B ^b   Bonini, S ^b   Bousquet, J ^b   Djukanovic, R ^b   Dreborg, S ^b   Gereda, J ^b   Malling, H J ^b   Popov, T ^b   Raz, E ^b   Renz, H ^b   Wold, A ^b  

^a BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BACILLUS SEPTUS EXTRACT; BACTERIAL PROTEIN; BACTERIUM LIPOPOLYSACCHARIDE; BACTERIUM LYSATE; GRASS POLLEN EXTRACT; HAEMOPHILUS INFLUENZAE EXTRACT; IMMUNOGLOBULIN A; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 2; KLEBSIELLA PNEUMONIAE EXTRACT; LACTOBACILLUS ACIDOPHILUS EXTRACT; LACTOBACILLUS RHAMNOSUS EXTRACT; MICROCOCCUS CATARRHALIS EXTRACT; MYCOBACTERIUM VACCAE EXTRACT; NEISSERIA CATARRHALIS EXTRACT; PHOSPHORYL LIPID A; PNEUMOCOCCUS EXTRACT; PROBIOTIC AGENT; PROTEUS MIRABILIS EXTRACT; PSEUDOMONAS AERUGINOSA EXTRACT; STAPHYLOCOCCUS ALBUS EXTRACT; STAPHYLOCOCCUS AUREUS EXTRACT; STREPTOCOCCUS HAEMOLYTICUS EXTRACT; STREPTOCOCCUS PYOGENES EXTRACT; STREPTOMYCES VIRIDANS EXTRACT; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; ALLERGY; ANEMIA; ARTICLE; CHILD; CONFUSION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; GASTROINTESTINAL SYMPTOM; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; IMMUNE RESPONSE; IMMUNOSTIMULATION; IMMUNOTHERAPY; INFLAMMATION; MENINGITIS; MOUSE; NONHUMAN; PAIN; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; RASH; SIDE EFFECT; SMALL INTESTINE OBSTRUCTION; TREATMENT OUTCOME;

ANIMALS; BACTERIA; BIOLOGICAL PRODUCTS; HUMANS; HYPERSENSITIVITY; PREVENTIVE MEDICINE; PROBIOTICS; TISSUE EXTRACTS;

EID: 0038017327     PISSN: 01054538     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1398-9995.2003.00175.x     Document Type: Article

References (88)

1. MARTINEZ FD, HOLT PG. Role of microbial burden in aetiology of allergy and asthma. Lancet 1999; 354(sII):12-15.
2. COOKSON WOCM, MOFFATT MF. Asthma: an epidemic in the absence of infection? Science 1997;275:41-42.
3. HOLT PG, SLY PD, BJORKSTEN B. Atopic versus infectious diseases in childhood: a question of balance? Pediatr Allergy Immunol 1997;8:53-58.
4. MATRICARDI PM. Infections preventing atopy: facts and new questions. Allergy 1997;52:879-882.
5. HOLGATE ST. Science, medicine, and the future. Allergic disorders. BMJ 2000;320:231-234.
6. WYBRAN J, LIBIN M, SCHANDENE L. Activation of natural killer ceils and cytokine production in humans by bacterial extracts (OM-85 BV). Lung 1990;168(Suppl):720-725.
7. MAUEL J. Stimulation of immunoprotective mechanisms by OM-85 BV. A review of results from in vivo and in vitro studies. Respiration 1994;61(Suppl 1):8-15.
8. KEUL R, ROTH M, PAPAKONSTANTINOU E, NAUCK M, PERRUCHOUD AP, BLOCK LH. Induction of interleukin 6 and interleukin 8 expression by Broncho-Vaxom (OM-85 BV) via C-Fos/serum responsible element. Thorax 1996;51:150-154.
9. ROTH M, BLOCK LH. Distinct effects of Bronch-Vaxom (OM-85 BV) on gp130 binding cytokines. Thorax 2000;55:678-684.
10. DURHAM SR, YING S, VARNEY VA. Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of ceils expressing messenger RNA for interferon-gamma. J Allergy Clin Immunol 1996;97:1356-1365.
11. BENE MC, KAHL L, PERRUCHET AM, HERMES H, MOSGES M, NORMIER G, BINZ H, FAURE GC. Bacterial lysates and ribosomes as inducers of specific immune responses: a comparative study. Scand J Immunol 1993;38:496-498.
12. OEHLING A. Bacterial immunotherapy in bronchial asthma. J Investig Allergol Clin Immunol 1997;7:14-19.
13. MALLING H-J. Bacterial vaccines: anything but placebo. Allergy 2000;55:214-218.
14. OEHLING A, JEREZ J, NEFFEN H, SANCHEZ PALACIOS A. Bacterial immunotherapy in bronchial asthma. Allergol Immunopathol (Madr) 1979;7:47-54.
15. OEHLING A, BAENA-CAGNANI CE, NEFFEN H. Bacterial immunotherapy of childhood bronchial asthma. Allergol Immunopathol (Madr) 1980;8:177-184.
16. FRANKLAND AW, HUGHES WH, GORRILD RH. Autogenous bacterial vaccines in the treatment of asthma. BMJ 1955;2:941-944.
17. FONTANA VJ, SALANITRO AS, WOLFE HI, MORENO F. Bacterial vaccines and infectious asthma. JAMA 1965;193:123-128.
18. KOIVIKKO A. Bacterial vaccine in childhood asthma. Acta Allergol 1973;28:202-210.
19. MUELLER HL, LANZ M. Hyposensitization with bacterial vaccine in infectious asthma. A double-blind study and a longitudinal study. JAMA 1969;26:1379-1383.
20. OHELING A. Importance of bacterial infection in the ethiopathogenesis of bronchial asthma. In: CHANEZ P, BOUSQUET J, MICHEL FB, GODARD P (editors). From genetics to quality of life. The optimal treatment and management of asthma. Seattle, WA: Hogrefe & Huber, 1996. pp. 119-126.
21. Global strategy for asthma management and prevention. WHO/NHLBI workshop report. NIH, NHLBI, Publication no. 95-3659, 1995.
22. MALLING HJ, WEEKE B (eds). Immunotherapy. EAACI position paper. Allergy 1993;48(Suppl 14):9-45.
23. BOUSQUET J, LOCKEY RF, MALLING HJ (editors). Allergen immunotherapy: therapeutic vaccines for allergic diseases. WHO position paper. Allergy 1998;53(Suppl 44):1-42.
24. SCHREZENMEIER J, DE VRESE M. Probiotics, prebiotics, and synbiotics -approaching a definition. Am J Clin Nutr 2001;73:361S-364S.
25. HALPERN GM, VRUWINK KG, VAN DER WATER J, KEEN CL, GERSHWIN ME. Influence of long-term yoghurt consumption in young adults. Int. J. Immunother. 1990;7:207-210.
26. WHEELER JG, BOGLE ML, SHEMA SJ, SHIRRELL MA, STINE KC, PITTLER AJ BURKS AW HELM RM. Impact of dietary yoghurt on immune function. Am. J. Med. Sci. 1997;313:120-123.
27. WHEELER JG SHEMA SJ, BOGLE ML, SHIRRELL MA, BURKS AW, PITTLER A, HELM RM. Immune and clinical impact of Lactobacillus acidophilus on asthma. Ann Allergy Asthma Immunol 1997;79:229-233.
28. SCHIFFRIN EJ, ROCHAT F, LINKAMSTER H, AESCHLIMANN JM, DONNET-HUGHES A. Immunomodulation of human blood cells following the ingestion of lactic acid bacteria. J Dairy Sci 1995;78:491-497.
29. DONNET-HUGHES A, ROCHAT F, SERRANT P, AESCHLIMANN JM, SCHIFFRIN EJ Modulation of nonspecific mechanisms of defense by lactic acid bacteria: effective dose. J Dairy Sci 1999;82:863-869.
30. ARUNACHALAM K, GILLS HS, CHANDRA RK. Enhancement of natural immune function by dietary consumption of Bifidobacterium lactis (HN019). Eur J Clin Nutr 2000;54:263-267.
31. PELTO L, ISOLAURI, E., LILIUS EM, NUUTILA J, SALMINEN S. Probiotic bacteria down-regulate the milk-induced inflammatory response in milk-hypersensitive subjects but have an immunostimulatory effect in healthy subjects. Clin Exp Allergy 1998;28:1474-1479.
32. HESSLE C, ANDERSSON B, WOLD AE. Gram-positive bacteria are potent induccers of IL-12 from human monocytes while Gram-negative bacteria preferentially induce IL-10 production. Infect. Immun. 2000;68:358:1-6.
33. HESSLE C, HANSON LÅ, WOLD AE. Lactobacilli colonizing the human gastro-intestinal tract are potent inducers of IL-12. Clin Exp Immunol 1999;116:276-282.
34. ADLERBERTH I, CARLSSON B, DE MAN P, JALIL F, KHAN SR, LARSSON P, MELLANDER L, SVANBORG C, WOLD AE, HANSON LÅ. Intestinal colonization with Enterobacteriaceae in Pakistani and Swedish hospital delivered infants. Acta Paediatr Scand 1991;80:602-610.
35. BENNET R, ERIKSSON M, TAFARI N, NORD C-E. Intestinal bacteria of newborn ethiopian infants in relation to antibiotic treatment and colonization with potentially pathogenic Gram-negative bacteria. Scand J Infect Dis 1991;23:63-69.
36. SEPP E, JULGE K, VASAR M, NAABER P, BJÖRKSTÉN B, MIKELSAAR M. Intestinal microflora of Estonian and Swedish infants. Acta Paediatr. 1997;86:956-961.
37. ADLERBERTH I, HANSON LÅ, WOLD AE. Ontogeny of the intestinal flora. In: SANDERSON IR, WALKER WA eds. Development of the Gastrointestinal Tract. B.C. Decker Inc., Hamilton, Ontario, 1999. pp. 279-292.
38. BJÖRKSTÉN B, NAABER P, SEPP E, MIKELSAAR M. The intestinal microflora in allergic Estonian and Swedish 2-year-old children. Clin Exp Allergy 1999;29:342-346.
39. KALLIOMAKI M, KIRJAVAINEN P, EEROLA E, KERO P, SALMINEN S, ISOLAURI E. Distinct patterns of neonatal gut microflora in infants in whom atopy was and was not developing. J Allergy Clin Immunol 2001;107:129-134.
40. BJORKSTEN B, SEPP E, JULGE K, VOOR T, MIKKELSAAR M. Allergy development and the intestinal microflora during the first year of life. J Allergy Clin Immunol 2001;108:516-520.
41. MAJAMAA H, ISOLAURI E. Probiotics: a novel approach in the management of food allergy. J Allergy Clin Immunol 1997;99:179-185.
42. ISOLAURI E, ARVOLA T, SUTAS Y, MOILANEN E, SALMINEN S. Probiotics in the management of atopic eczema. Clin Exp Allergy 2000;30:1604-1610.
43. HELIN T, HAAHTELA S, HAAHTELA T. No effect of oral treatment with an intestinal bacterial strain, Lactobacillus rhamnosus (ATCC 53103), on birch pollen allergy - A placebo-controlled double-blind study. Allergy 2002;37:243-246.
44. KALLIOMAKI M, SALMINEN S, ARVILOMMI H, KERO P, KOSKINEN P, ISOLAURI E. Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. Lancet. 2001;357:1076-1079.
45. HATA D, YOSHIDA A, OHKUBO H, MOCHIZUKI Y, HOSOKI Y, TANAKA R. Meningitis caused by bifidobacterium in an infant. Pediatr Infect Dis 1988;7:669-671.
46. BARTON LL, RIDER ED, COEN RW. Bacteremic infection with Pediococcus: vancomycin-resistant opportunist. Pediatrics 2001;107:775-776.
47. ROOK G. Gives us this day our daily germs. Immunol Today 1998;19:113-116.
48. WANG CC, ROOK GA. Inhibition of an established allergic response to ovalbumin in BALB/c mice by killed Mycobacterium vaccae. Immunology 1998;93:307-313.
49. SHIRAKAWA T, ENOMOTO T, SHIMAZU S, HOPKIN JM. The inverse association between tuberculin responses and atopic disorder. Science 1997;275:77-79.
50. SHIRTCLIFFE PM, EASTHOPE SE, CHENG S, WEATHERALL M, TAN PL, LE GROS G, BEASLEY R. The effect of delipidated deglycolipidated (DDMV) and heat-killed Mycobacterium vaccae in asthma. Am J Respir Crit Care Med 2001 May;163:1410-1414.
51. ARKWRIGHT PD, DAVID TJ. Intradermal administration of a killed Mycobacterium vaccae suspension (SRL 172) is associated with improvement in atopic dermatitis in children with moderate-to-severe disease. J Allergy Clin Immunol 2001;107:531-534.
52. MARAVEYAS A, BABAN B, KENNARD D, ROOK GA, WESTBY M, GRANGE JM, LYDYARD P, STANFORD JL, JONES M, SELBY P, DALGLEISH AG. Possible improved survival of patients with stage IV AJCC melanoma receiving SRL 172 immunotherapy: correlation with induction of increased levels of intracellular interleukin-2 in peripheral blood lymphocytes. Ann Oncol 1999;10:817-824.
53. RAZ E, TIGHE H, SATO Y, CORR M, DUDLER JA, ROMAN M, et al. Preferential induction of a Th1 immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization. Proc Natl Acad Sci U S A 1996;93:5141-5145.
54. SATO Y, ROMAN M, TIGHE H, LEE D, CORR M, NGUYEN MD, et al. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science 1996;273:352-354.
55. ROMAN M, MARTIN-OROZCO E, GOODMAN JS, NGUYEN MD, SATO Y, RONAGHY A, et al. Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat Med 1997;3:849-854.
56. BIRD AP. DNA methylation and the frequency of CpG in animal DNA. Nucleic Acids Res 1980;8:1499-1504.
57. BAUER M, HEEG K, WAGNER H, LIPFORD GB. DNA activates human immune cells through a CpG sequence-dependent manner. Immunology 1999;97:699-705.
58. HESSLE C, ANDERSSON B, WOLD AE. Gram-positive bacteria are potent inducers of monocytic interleukin-12 (IL-12) while Gram-negative bacteria preferentially stimulate IL-10 production. Infect Immun 2000;68:3581-3586.
59. HORNER AA, VAN UDEN JH, ZUBELDIA JM, BROIDE D, RAZ E. DNA-based immunotherapeutics for the treatment of allergic disease. Immunology Reviews 2001;179:102-118.
60. HORNER AA, NGUYEN MD, RONAGHY A, CINMAN N, VERBEEK S, RAZ E. DNA-based vaccination reduces the risk of lethal anaphylactic hypersensitivity in mice. J Allergy Clin Immunol 2000;106:349-356.
61. BROIDE D, SCHWARZE J, TIGHE H, GIFFORD T, NGUYEN MD, MALEK S, et al. Immunostimulatory DNA sequences inhibit IL-5, eosinophilic inflammation, and airway hyperresponsiveness in mice. Journal of Immunology 1998;161:7054-7062.
62. MAGONE MT, CHAN CC, BECK L, WHITCUP SM, RAZ E. Systemic or mucosal administration of immunostimulatory DNA inhibits early and late phases of murine allergic conjunctivitis. Eur J Immunol 2000;30:1841-1850.
63. PARRONCHI P, BRUGNOLO F, ANNUNZIATO F, MANUELLI C, SAMPOGNARO S, MAVILIA C, ROMAGNANI S, MAGGI E. Phosphorothioate oligodeoxynucleotides promote the in vitro development of human allergen-specific CD4 + T cells into Th1 effectors. J Immunol 1999;163:5946-5953.
64. BOHLE B, JAHN-SCHMID B, MAURER D, KRAFT D, EBNER C. Oligodeoxynucleotides containing CpG motifs induce IL-12, IL-18 and IFN-gamma production in cells from allergic individuals and inhibit IgE synthesis in vitro. Eur J Immunol 1999;29:2344-2353.
65. HORNER AA, WIDHOPF GF, BURGER JA, TAKABAYASHI K, CINMAN N, RONAGHY A, SPIEGELBERG HL, RAZ E. Immunostimulatory DNA inhibits IL-4-dependent IgE synthesis by human B cells. J Allergy Clin Immunol 2001;108:417-423.
66. MARSHALL JD, ABTAHI S, EIDEN JJ, TUCK S, MILLEY R, HAYCOCK F, REID MJ, KAGEY-SOBOTKA A, CRETICOS PS, LICHTENSTEIN LM, VAN NEST G. Immunostimulatory sequence DNA linked to the Amb a 1 allergen promotes T(H)1 cytokine expression while downregulating T(H)2 cytokine expression in PBMCs from human patients with ragweed allergy. J Allergy Clin Immunol 2001;108:191-197.
67. VERTHELYI D, KENNEY RT, SEDER RA, GAM AA, FRIEDAG B, KLINMAN DM. CpG oligodeoxynucleotides as vaccine adjuvants in primates. J Immunol 2002;168:1659-1663.
68. TIGHE H, TAKABAYASHI K, SCHWARTZ D, VAN NEST G, TUCK S, EIDEN JJ, et al. Conjugation of immunostimulatory DNA to the short ragweed allergen amb a 1 enhances its immunogenicity and reduces its allergenicity. J Allergy Clin Immunol 2000;106:124-134.
69. CRETICOS PS, BALCER SL, SCHRODER JT, HAMILTON RG, CHUNG B, NORMAN P, LICHTENSTEIN L, EIDEN JJ. Initial immunotherapy trial to explore the safety, tolerability, and immunogenicity of subcutaneous injection of the AMBa1 Immunostimulatory oligodeoxynucleotide conjugate (AIC) in ragweed allergic adults [abstract]. J Allergy Clin Immunol 2001;107:S216.
70. SPIEGELBERG HL, RAZ E. DNA-based approaches to the treatment of allergies. Curr Opin Mol Ther 2002;4:64-71.
71. ULRICH JT, MYERS KR. Monophosphoryl Lipid A as an adjuvant. In: POWELL, MF, NEWMAN, MJ (Editors). Vaccine design: the subunit and adjuvant approach. Plenum Press, New York, 1995.
72. DRACHENBERG KJ, WHEELER AW, STUEBNER P, HORAK F. A well-tolerated grass pollen specific allergy vaccine containing a novel adjuvant, Monophosphoryl Lipid A reduces allergic symptoms after only four preseasonal injections. Allergy 2001;56:498-505.
73. TULIC MK, WALE JL, HOLT PG, SLY PD. Modification of the inflammatory response to allergen challenge after exposure to bacterial lipopolysaccharide. Am J Respir Cell Mol Biol 2000;22:604-612.
74. MYERS K, BEINING P, BETTS M, SNIPPE H, INMAN J, GOLDING B. Monophosphoryl lipid A behaves as a T-cell independent type 1 carrier for hapten-specific antibody responses in mice. Infect Immun 1995;63:168-174.
75. SALKOWSKI CA, DETORE GR, VOGEL SN. Lipopolysaccharide and Monophosphoryl Lipid A differentially regulate interteukin-12, gamma interferon, and interleukin-10 mRNA production in murine macrophages. Infect Immunity 1997;65:3239-3247.
76. HENRICSON BE, BENJAMIN WR, VOGEL SN. Differential cytokine induction by doses of lipopolysaccharide and monophosphoryl lipid A that result in equivalent early endotoxin tolerance. Infect Immun 1990;58:2429-2437.
77. BALDRIDGE JR, YORGENSEN Y, WARD JR, ULRICH JT. Monophosphoryl lipid A enhances mucosal and systemic immunity to vaccine antigens following intranasal administration. Vaccine 2000;18:2416-2425.
78. WHEELER AW, MARSHALL JS, ULRICH JT. A Th1-inducing adjuvant, MPL, enhances antibody profiles in experimental animals suggesting it has the potential to improve the efficacy of allergy vaccines. Int Arch Allergy Immunol 2001;126:135-139.
79. GEREDA JE, LEUNG DY, THATAYATIKOM A, STREIB JE, PRICE MR, KLINNERT MD, LIU AH. Relation between house-dust endotoxin exposure, type 1 T-cell development, and allergen sensitisation in infants at high risk of asthma. Lancet 2000;355:1680-1683.
80. DOUWES J, PEARCE N, HEEDERIK D. Does environmental endotoxin exposure prevent asthma?. Thorax 2002;57:86-90.
81. REED CE, MILTON DK. Endotoxin-stimulated innate immunity: A contributing factor for asthma. J Allergy Clin Immunol 2001;108:157-166.
82. BALDRICK P, RICHARDSON D, WHEELER AW. Safety evaluation of glutaraldehyde modified tyrosine adsorbed house dust mite extract containing monophosphoryl lipid A (MPL((R))) adjuvant: a new allergy vaccine for dust mite allergy. Vaccine 2001;20:737-743.
83. TAKAYAMA K, QUERESHI N, RIBI E, CANTRELL JL. Separation and characterization of toxic and on toxic forms of lipid A. Rev Infect Dis 1984;6:439-443.
84. THOELEN S, VAN DAMME P, MATHEI C, et al. Safety and immunogenicity of a hepatitis B vaccine formulated with a novel adjuvant system. Vaccine 1998;16:708-714.
85. HEPPNER DG, GORDON DM, GROSS M, et al. Safety, immunogenicity and efficacy of Plasmodium falciparum repetless circumsporozoite protein vaccine encapsulated in liposomes. J Infect Diseases 1996;174:361-366.
86. LIU AH, REDMON AH Jr. Endotoxin: friend or foe? Allergy Asthma Proc 2001;22:337-340.
87. KARP MW, SANTELIZ J, KARP CL. The germless theory of allergic disease: revisiting the hygiene hypothesis. Nat Rev Immunol 2001;1:69-75.
88. YAZDANBAKHSH M, KREMSUER PG, VAN REE R. Allergy, parasites and the hygiene hypothesis. Science 2002;296:490-494.